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An important precondition for the successful devel-
opment of diagnostic assays of cerebrospinal fluid
(CSF) biomarkers of age-related neurodegenerative
diseases is an understanding of the dynamic nature of
the CSF proteome during the normal aging process.
In this study, a novel proteomic technology was used
to quantify hundreds of proteins simultaneously in
the CSF from 90 cognitively normal adults 21 to 85
years of age. SomaLogic’s highly multiplexed pro-
teomic platform can measure more than 800 proteins
simultaneously from small volumes of biological flu-
ids using novel slow off-rate modified aptamer
(SOMAmer) protein affinity reagents with sensitivity,
specificity, and dynamic ranges that meet or exceed
those of enzyme-linked immunosorbent assays. In
the first application of this technology to CSF, we
detected 248 proteins that possessed signals greater
than twofold over background. Several novel correla-
tions between detected protein concentrations and
age were discovered that indicate that both inflamma-
tion and response to injury in the central nervous
systemmay increase with age. Applying this powerful
proteomic approach to CSF provides potential new
insight into the aging of the human central nervous
system that may have utility in discovering new dis-
ease-related changes in the CSF proteome. (Am J
Pathol 2012, 180:446–456; DOI: 10.1016/j.ajpath.2011.10.024)
Research focused on understanding and treating neuro-
degenerative disorders such as Alzheimer’s disease
446(AD) or Parkinson’s disease (PD) will benefit greatly from
validated laboratory diagnostic methods to aid in diag-
nosing, quantifying progression, and assessing response
to therapeutics. Laboratory diagnostic approaches to
central nervous system (CNS) disorders are hampered
by sampling issues. It is dangerous, impractical, and
costly to directly sample CNS tissue by surgical biopsy;
and, even when performed, the results of brain biopsy
are often uninformative for directing a change in ther-
apy.1 On the other hand, sampling blood or urine is
relatively simple, but informative biomarkers of CNS dis-
ease are not always transmitted from the CNS to the
peripheral circulation or may not be observed because of
dilution. Efforts to find blood or urine tests for degenerative
CNS disease have not yet yielded any clinically useful as-
says.2 Thus, efforts to diagnose neurological disorders such
as AD have concentrated on cerebrospinal fluid (CSF),3,4 a
fluid that is in direct contact with CNS tissue, yet is relatively
easy to sample in a safe procedure (lumbar puncture) that
can be performed in the outpatient setting.5
CSF is by no means a perfect diagnostic sample.
Aside from considerable public concern over the so-
called “spinal tap,” there are several reasons why the
fluid itself is not an optimal substrate from which to re-
cover diagnostically informative biomarkers. First, al-
though CSF is partly derived from brain interstitial fluid, it
is largely a transudate of plasma produced by choroid
plexus.6,7 Second, CSF is recycled up to six times per
day, possibly limiting the persistence of potential bio-
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sampling CSF is safe and relatively straightforward in
skilled hands, blood contamination is possible and can
complicate collection and confound analysis.
Despite these potential limitations, the evidence support-
ing use of CSF biomarker-based diagnosis of CNS disease
is increasing, especially for AD. CSF concentrations of A42
and tau have been found to significantly decrease and
increase, respectively, in patients who have AD or are at
increased risk for obtaining a future diagnosis of AD.8–10
Research assays for these analytes are available, as is a
commercial clinical assay (Athena Diagnostics ADmark as-
say, which also measures phosphorylated tau).
There is now an intense research effort to discover
additional biomarkers to diagnose other age-related neu-
rodegenerative diseases, to quantify progression, and to
assess therapeutic response. Because neurodegenera-
tive diseases like AD occur predominantly in older indi-
viduals, a key component of disease-focused biomarker
discovery efforts will be a full understanding of the age-
related changes in CSF that occur independently of
disease. In addition, understanding the age-related
changes in the CSF proteome will likely provide insight
into the biology of aging in the CNS.
Although there have been numerous reports investi-
gating the CSF proteome,11–15 as well as age-related
changes in specific CSF biomarkers during the course of
other studies,16–18 we are only aware of only one previ-
ous study that has taken an unbiased approach toward
studying the entire CSF proteome in aging.19 Using an
isotope labeling strategy paired with mass spectrometry
(ICAT, for Isotope-Coded Affinity Tags), Zhang et al iden-
tified peptides corresponding to CSF proteins. Relative
quantitation was implied by the mass spectrometry tech-
nique used, and confirmed by Western blot in a selected
small subset of proteins, as a mass spectrometric pro-
teomic approach could not be easily translated into a
high-throughput assay. This limitation exemplifies a prob-
lem with current mass spectrometry–based approaches
to proteomics; namely, proteomic biomarker discoveries
made with mass spectrometry are often difficult to trans-
late into clinically feasible assays. Furthermore, although
mass spectrometry–based approaches have great
promise in clinical proteomics, many challenges remain
including issues of sensitivity (typically nmol/L in current
approaches), quantification, specificity, reproducibility,
throughput, and cost.20–25
Although immunoassays are currently preferred for tar-
geted clinical assays, they often are not used in primary
biomarker discovery efforts. Instead, the traditional pipe-
line for biomarker discovery has focused on mass spec-
trometric discovery of biomarkers followed by validation
on targeted immunoassay platforms. This is because it is
currently not possible to run immunoassays in high
enough multiplex, ie, hundreds or thousands of analytes
per assay, to effectively query a sufficient number of
potential biomarkers in each clinical sample.26
Slow off-rate modified aptamers (SOMAmers) are a
new class of aptamer binding reagents that contain novel
chemically modified nucleotides and are selected with a
novel systematic evolution of ligands by exponential en-richment (SELEX) process to have slow dissociation
rates.27 SOMAmers enable multiplex quantitative mea-
surements of thousands of proteins with sensitivity, spec-
ificity, and dynamic range that meet or exceed those of
enzyme-linked immunosorbent assays.27 In these as-
says, SOMAmers are used in high multiplex (1000 si-
multaneous measurements presently) as binding re-
agents to quantify proteins in biological samples. In
contrast to mass spectrometric assays, SOMAmer arrays
use target-binding reagents that are not interfered with by
noninformative, high-concentration proteins such as al-
bumin. Because SOMAmer target affinities are on par
with monoclonal antibodies (sub-nM Kd), SOMAmers can
detect proteins at far lower concentrations than is possi-
ble in traditional discovery-mode shotgun mass spectro-
metric techniques while still detecting many proteins at
once. Another distinct advantage of SOMAmer-based
discovery is that SOMAmer-derived biomarker discover-
ies can, in principle, easily be converted to targeted
assays because the reagents used for discovery and
targeted assays are identical,28 obviating the need for
prolonged efforts to translate findings to a separate plat-
form. Novel SOMAmer discovery is also automated, tak-
ing a matter of days to weeks to generate candidate
reagents for validation, as opposed to antibody genera-
tion in animals or cell culture, which can take weeks to
months to generate reagent candidates.
Materials and Methods
Patient Samples
The Human Subjects Division at the University of Wash-
ington approved this study to collect specimens and
analyze results from human subjects. Subjects were
compensated community volunteers in good health, with
no signs or symptoms suggesting cognitive decline or
neurological disease. After providing written informed
consent, all individuals underwent evaluation that con-
sisted of medical history; physical and neurological
examinations; laboratory tests (complete blood count,
serum electrolytes, blood urea nitrogen, creatinine, glu-
cose, vitamin B12, and thyroid-stimulating hormone), as
well as neuropsychological assessment that consisted of
the Mini-Mental State Examination (MMSE),29 memory
tests including immediate and delayed Paragraph Recall
as well as Category Fluency and Letter Fluency30,31 and
parts A and B of the Trail Making Test as a measure of
attention.32 All results were within normal limits for sam-
ples included in this study. Exclusion criteria were heavy
cigarette smoking (10 packs/yr), alcohol use other than
social, or any psychotherapeutic use.
CSF was obtained by lumbar puncture as previously
described.33 Briefly, after providing written informed con-
sent, individuals were placed in the lateral decubitus
position and the L4 to L5 interspace was infiltrated with
1% lidocaine. Lumbar puncture was performed with a
20-gauge or 24-gauge spinal needle, after which individ-
uals remained at bed rest for 1 hour. All lumbar punctures
were performed in the morning to limit potential circadian
(table continues)
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analysis was obtained from the 15th to 25th milliliter col-
lected, stored in 0.5-mL aliquots at 80°C, and never
thawed before this study. Red blood cell (RBC) counts
from samples averaged 14  42 RBC/L, and 83% of
samples had RBC counts 10 RBC/L (see Supplemen-
tal Figure S1 at http://ajp.amjpathol.org).
Assay Methodology
Details of the SOMAmer array technology and assay
methodology have been reported elsewhere in great de-
tail,27 but specific modifications used to adopt the tech-
nique to CSF follow. Briefly, oligonucleotides bearing
modified nucleotide bases (SOMAmers) were produced
in vitro to bind to 813 human proteins27 comprising a wide
variety of different functional classes: 20% cytokines,
13% growth factors, 21% receptors, 17% proteases, 5%
protease inhibitors, 20% kinases, 1% structural proteins,
and 3% hormones. The protein targets were chosen
based on literature reports of involvement in a wide vari-
ety of biological and pathophysiological processes (for
description of protein targets, see Supplemental Table S1
and Supplemental Figure S2, available at http://ajp.
amjpathol.org). Of note, the targets were not chosen to
represent the entire CSF proteome, nor were they chosen
for their specific relevance to CNS tissue, neurodegen-
eration, or aging. Specifically, although a SOMAmer to
tau is included in the target list, no SOMAmer to A42 is
currently available.
Sample Thawing and Plating
Aliquots of 100% CSF, stored at 80°C, were thawed by
incubating in a 25°C water bath for 10 minutes. After
thawing, the samples were stored on ice before assay.
An 80% sample solution was prepared by transferring 64
L of thawed sample into the well of a 96-well plate
(Hybaid Omnitube 0.3 mL, Fisher Scientific) containing
16 L per well of the appropriate sample diluent at 4°C.
Sample diluent was 0.2x SB17 (8 mmol/L HEPES, pH 7.5,
25 mmol/L NaCl, 1 mmol/L KCl, 0.2 mmol/L MgCl2, 0.2
Table 1. Continued
SOMAmer target
Pearson correlation
coefficient
UniProt
accession ID
Angiogenin 0.40 P03950
HMW kininogen 0.39 P01042
TRAILR4 0.39 Q9UBN6
FSH 0.38 P01215
NovH 0.38 P48745
Gr. V Phospholipase A2 0.38 P39877
Cystatin C 0.39 P01034
DRR1 0.44 O95990
Troponin I 0.45 P19429
IGF.I 0.45 P01343
BMP.14 0.45 P43026
Pleiotrophin 0.47 P21246
MIP.3b 0.52 Q99731Table 1. Candidate Biomarkers of Aging Identified with the
Slow Off-Rate Modified Aptamer (SOMAmer) Platform
SOMAmer target
Pearson correlation
coefficient
UniProt
accession ID
TNFsR.II 0.81 P20333
Activin A 0.76 P08476
Factor D 0.74 P00746
SLPI 0.72 P03973
BCAM 0.70 P50895
C7 0.69 P10643
vWF 0.69 P04275
TNFsR.I 0.67 P19438
ERBB3 0.67 P21860
CD30 0.66 P28908
Ephrin.A4 0.64 P52798
HGF 0.63 P14210
IGFBP.4 0.63 P22692
TIMP-1 0.61 P01033
Trypsin 0.61 P07477
Laminin 0.60 P25391
HCC.1 0.60 Q16627
suPAR 0.60 Q03405
1-Antichymotrypsin 0.59 P01011
JAM.C 0.59 Q9BX67
sTie.1 0.59 P35590
Endostatin 0.58 P39060
CXCL16.soluble 0.57 Q9H2A7
IL.1sRI 0.56 P14778
ART 0.56 O00253
Fibrinogen 0.55 P02671
Siglec.7 0.54 Q9Y286
C1q 0.53 P02747
Myoglobin 0.53 P02144
Angiopoietin.1 0.52 Q15389
GFAP 0.52 P14136
DC.SIGN 0.51 Q9NNX6
C4b 0.51 P0C0L4
Lysozyme 0.51 P61626
C3 0.51 P01024
ROR1 0.51 Q01973
Siglec.3 0.50 P20138
iC3b 0.50 P01024
Ceruloplasmin 0.50 P00450
APRIL 0.50 O75888
C9 0.50 P02748
Ephrin.A5 0.49 P52803
C3adesAr 0.49 P01024
Cadherin.5 0.49 P33151
LBP 0.49 P18428
PARC 0.49 P55774
Sonic Hedgehog 0.48 Q15465
PIGF 0.48 P49763
C3a 0.48 P01024
ESAM 0.47 Q96AP7
Angiopoietin.2 0.47 O15123
Protein C 0.46 P04070
TWEAK 0.46 O43508
MMP.8 0.46 P22894
Dtk 0.46 Q06418
TIG2 0.45 Q99969
TGF.bRIII 0.44 Q03167
IGFBP.5 0.44 P24593
HCC.4 0.44 O15467
SCGF.alpha 0.43 Q9Y240
IL.1RAcP 0.43 Q9NPH3
ERBB1 0.43 P00533
Factor I 0.43 P05156
Protein S 0.42 P07225
DAN 0.42 P41271
SCGF.beta 0.41 Q9Y240
Lipocalin2 0.40 P80188
bFGF.R 0.40 P11362mmol/L CaCl2). with 2.56 mmol/L MgCl2, 2 mol/L Z-
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AC),27 and 0.05% Tween.
Preparation of 40%, 4%, and 0.4% SOMAmer
Solutions
Because target analyte concentrations vary widely in CSF,
analyses were performed on three different CSF dilutions.
To determine which SOMAmers should be used at each
dilution, SOMAmer targets were assayed in a serum dilution
series to define pools of SOMAmers giving the largest linear
range of signal at each dilution. Pools of SOMAmers de-
fined in this manner were then adapted to CSF by ensuring
large linear signal ranges on diluted CSF. In this manner,
segregating SOMAmers and mixing them with different
sample dilutions (40%, 4%, and 0.4%) allowed the assay to
span an expected range of protein concentrations in CSF.
Signal Quantitation
The signals for each protein were quantitated as relative
fluorescence units (RFUs) on the oligonucleotide array used
to make the final measurement, as indicated.27 Although
calibration curves relating protein concentrations to RFU val-
ues can be derived, the purpose of this study was to identify
relative, rather than absolute, changes in protein concentra-
tions with age, and thus all analysis was performed on raw
RFU values. In general, SOMAmer RFU signals are nearly
linear with respect to target concentration for the targets
discussed here (data not shown).
Spike and Recovery
Spike and recovery experiments were performed by
the same assay methodology on samples prepared
from spiked proteins added to two separate pooled
lumbar CSF samples (Bioreclamation, Hicksville, NY).
Spiked proteins included a selection of biomarkers
from Table 1: BCAM, BMP-14, C7, cystatin C, Ephrin-
A4, ERBB3, Factor D, HGF, IGFBP-4, PTN, TIMP-1, TNF
sR-II, and Troponin I. Additional information for source
proteins (commercial vendor, city, state, part number,
recombinant/purified, biological source) is listed here:
TNF sR-II (R & D Systems, Minneapolis, MN, 726-R2-
050, recombinant, murine myeloma cell line, NS0 de-
rived), BCAM (R & D Systems, 148-BC-100/CF, recom-
binant, murine myeloma cell line, NS0 derived),
BMP-14 (Pepro Tech, Rocky Hill, NJ, 120-01X, recom-
binant, Escherichia coli derived), Troponin I (Research
Diagnostics, Acton, MA, RDICARDTROPIB, purified,
human cardiac tissue), ERBB3 (R & D Systems, 348-
RB-050, recombinant, murine myeloma cell line, NS0
derived), Ephrin-A4 (R & D Systems, 369-EA-200/CF,
recombinant, murine myeloma cell line, NS0 derived),
HGF (R & D Systems, 294-HGN-025/CF, recombinant,
murine myeloma cell line, NS0 derived), Factor D
(VWR, Radnor, PA, 80051–580, purified, human), C7
(Quidel, San Diego, CA, A405, purified, human), PTN
(Pepro Tech, 450–15, recombinant, E. coli derived),
TIMP-1 (R & D Systems, 970-TM-010, recombinant,murine myeloma cell line, NS0 derived), IGFBP-4 (R &
D Systems, 804-GB-025, recombinant, murine my-
eloma cell line, NS0 derived), and Cystatin C (R & D
Systems, 1196-PI-010, recombinant, murine myeloma
cell line, NS0 derived).
Briefly, a master mix of all proteins at 2 nmol/L was
added to pooled CSF, yielding the following added
concentrations: 2000 pmol/L, 400 pmol/L, 80 pmol/L,
16 pmol/L, 3.2 pmol/L, 0.64 pmol/L, 0.128 pmol/L, and
0 pmol/L. Because the individual proteins have widely
varying endogenous concentrations, the CSF pool was
diluted at 40%, 3%, or 0.2% in SB buffer before spiking
so that the spiked concentration would be comparable
to the endogenous concentration somewhere over the
assay’s linear range. Of the spiked proteins, seven
proteins were spiked into 40% diluted CSF (BCAM,
BMP-14, Ephrin-A4, ERBB3, HGF, TNF sR-II, Troponin
I); five proteins were spiked into 3% diluted CSF (C7,
Factor D, IGFBP-4, TIMP-1, PTN); and one protein was
spiked into 0.2% diluted CSF (Cystatin C). Correspond-
ing dilutions into buffer only were performed as well
and used as a standard curve. Standard curve data
points were collected in triplicate, and spike data
points were collected in singlicate on each pool.
The target concentration measured in the 0-pmol/L
spiked sample (no added proteins) was subtracted
from the target concentrations measured in the other
samples to yield the recovered amount (for the ratio of
the recovered amount to the added amount, given as
the percent recovery, see Supplemental Table S2
available at http://ajp.amjpathol.org). Recovery was
only calculated for data points that were within the
linear range of the assay for each analyte.
Statistical Analysis
RFU signals for each protein target were tabulated and
analyzed using the R statistical package. Pearson correla-
tion coefficients of target RFUs to patient ages were derived
from the data, including the P values of the correlation
coefficients, and a Bonferroni correction (  0.05, 248
simultaneous analyses) was used to select significant cor-
relations among the potential biomarkers. In addition, prin-
cipal component analysis and principal component regres-
sion were used to assess for patterns of variation in the
log-transformed data that correlated with biological age.
Principal component regression was validated with the
“leave one out” method. To highlight patterns of change
due to aging, a mathematical manipulation known as dis-
ease-specific genomic analysis (DSGA34) was used to re-
move patterns of variation seen in young patients from the
middle and older aged data sets.
Bioinformatics Analysis of Biomarkers
The DAVID bioinformatics database of the National Insti-
tute of Allergy and Infectious Diseases (http://david.abcc.
ncifcrf.gov/home.jsp) was used to group biomarkers that
were found to vary significantly with age into classifica-
tions based on gene ontology. Proteins were entered into
the DAVID tool using the Uniprot Accession ID.
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Detecting Proteins in CSF with a SOMAmer Array
Of the 813 biomarker candidates assayed in this study,
248 were observed with signals greater than twofold over
Figure 1. Percent change in relative fluorescence unit signal between sub-
jects 21 and 85 years of age, estimated from linear regression, plotted against
Pearson correlation coefficients for biomarkers. Analytes with significant age
correlation after Bonferroni correction are shown with open boxes, and
remaining analytes are shown with crosses. Points corresponding to four
biomarkers with large and significant age-dependent changes are labeled.Figure 2. Plots of SOMAmer signal (y axis, relative fluorescence units) versus age
male subjects (open triangles) are identified in each plot.background levels in the 90 subjects. Spike and recovery
experiments performed on pooled lumbar CSF yielded a
median recovery of 104% (range 75.3% to 177.3%)
across various concentrations of selected targets (see
Supplemental Figure S3 and Supplemental Table S2 at
http://ajp.amjpathol.org). Although quantitation, in terms
of mass or moles of analyte per volume of CSF, is feasible
with this technique, many hundreds of standards would
have been needed to calibrate RFU values for individual
proteins. Because we were interested in defining relative
trends in biomarker concentration with age rather than with
absolute concentration, we chose not to include absolute
quantitation in the current study. We chose to use a twofold-
over-background cutoff for signals by examining the vari-
ance from negative control SOMAmers (either SOMAmers
with scrambled sequences or targeted to non-human pro-
teins), and chose a twofold cutoff as a compromise be-
tween increasing the number of SOMAmer signals detected
and decreasing the false-discovery rate.
Age-Dependent Changes in CSF Biomarkers
Correlation coefficients of those biomarkers that changed
significantly with age, as well as average change be-
tween ages 21 and 85 years, are listed in Table 1. Inter-
estingly, many more biomarkers were found to increase
than to decrease with increasing age.
In Figure 1, the estimated percent change in biomarker
RFU signal from age 21 to age 85 years (derived from(x axis, years) for selected biomarkers. Female subjects (closed circles) and
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coefficient for biomarker versus age. Note that RFU does
not scale perfectly linearly with target concentration, so this
percentage change is only a rough estimate of the magni-
tude of change. Because of the true log-linear or sigmoidal
relationship between RFU and concentration, the relative
changes in concentration of some biomarkers with agemay
be larger than the RFU changes suggest, such that a 100%
increase in RFU could correspond to more or less than a
100% increase in concentration. Althoughmany biomarkers
with significant age-dependent changes showed RFU sig-
nal elevations of 30% to 75% between younger and older
subjects, several of themost highly age-correlated biomark-
ers increased in RFU by more than 100% between younger
and older individuals.
Plots of target RFU from the SOMAmer array versus
age are shown in Figure 2 for some representative bio-
markers that changed in concentration with age. No sub-
jects 37 to 45 years of age were represented in this
cohort, explaining the bimodal appearance of the data.
Male and female subjects are shown with different sym-
bols to highlight that most biomarker concentration
changes were independent of sex, with the notable ex-
ception of follicle-stimulating hormone (FSH). Production
of FSH in the pituitary increases around the time of meno-
Figure 4. A: Principal component regression prediction of age by biomarker
cross-validation of principal component regression. Root-mean-squared erro
in the model. C: Principal component regression prediction of age by biomarker si
prediction.pause (40–60 years of age), indicating that this ap-
proach is able to detect expected and biologically sig-
nificant age-dependent changes in CSF.
Principal Component Analysis
Principal component analysis of the log-transformed bio-
marker data set was performed, with results shown in
Figure 3. Figure 3A is a scree plot demonstrating that
much, but not all, of the variation in the data were ex-
plained by a single principal component. After using
DSGA to remove the variation observed in subjects 21 to
40 years of age, principal components 1 and 2 were
plotted (Figure 3B). Subjects classified as younger (21 to
40 years), middle-aged (40 to 65 years), and older (65 to
85 years) were clearly separated by principal component
1, further indicating that the variation present in the first
principal component was correlated with age.
Principal Component Regression
Regression analysis of the of the first principal compo-
nent of biomarker data against subject age again showed
that the first principal component explained much, but
not all, of the age-dependent variance (Figure 4A) in the
Figure 3. A: Screeplot of principal component anal-
ysis from entire biomarker dataset. The first 10 prin-
cipal components, which cumulatively account for
70% of the total variance in the data set, are shown.
B: The first two principal components are plotted
after DSGA to remove variation observed in subjects
20 to 40 years of age.
e using only the first principal component. B: Results of leave-one-out (LOO)
iction (y axis) is plotted versus the number of components (x axis) includedsignatur
r of predgnature using the first 38 principal components, showing improved model
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AJP February 2012, Vol. 180, No. 2Table 2. Gene Ontology Analysis of Age-Varying Biomarker Candidates
Gene ontology classification*
Protein 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
TNFsR.II ● ● ●
Activin A ● ●
Factor D ● ● ● ● ● ● ●
SLPI
BCAM
C7 ● ● ● ● ● ● ●
vWF ● ● ● ●
TNFsR.I ● ● ● ●
ERBB3 ● ● ●
CD30 ●
Ephrin.A4
HGF ●
IGFBP.4 ● ● ●
TIMP-1 ● ●
Trypsin ●
Laminin ● ● ●
HCC-1 ● ●
suPAR ● ● ● ● ●
1-antichymotrypsin ● ● ●
JAM.C
sTie.1 ●
Endostatin ● ● ● ●
CXCL16.soluble ● ● ●
IL.1sRI ● ●
ART
Fibrinogen ● ● ● ● ●
Siglec.7
C1q ● ● ● ● ● ● ●
Myoglobin ● ●
Angiopoietin.1 ●
GFAP
DC.SIGN
C4b ● ● ● ● ● ● ●
Lysozyme ● ● ●
C3 ● ● ● ● ● ● ●
ROR1
Siglec.3 ●
iC3b ● ● ● ● ● ● ●
Ceruloplasmin
APRIL ● ● ●
C9 ● ● ● ● ● ● ● ● ● ●
Ephrin.A5
C3adesAr ● ● ● ● ● ● ●
Cadherin.5 ● ●
LBP ● ● ● ●
PARC ● ● ●
Sonic Hedgehog ● ● ● ● ● ● ● ● ● ● ●
PIGF ● ● ●
C3a ● ● ● ● ● ● ●
ESAM
Angiopoeitin.2 ●
Protein C ● ● ● ● ●
TWEAK ● ● ●
MMP.8 ● ●
Dtk
TIG2
TGF.bRIII ● ● ● ●
IGFBP.5 ● ● ●
HCC.4 ● ● ●
SCGF.alpha ● ●
IL.1RAcP ● ● ● ●
ERBB1 ● ● ● ●
Factor I ● ● ● ● ● ● ●
Protein S ● ● ● ●
DAN
SCGF.beta ● ●
Lipocalin2
bFGF.R ● ● ●(table continues)
ulature
; 17 
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incorporating more principal components into the regres-
sion analysis (Figure 4B), reaching a global minimum of
prediction error when including 38 principal components
in the model (Figure 4C). These results indicated that
there are multiple effects other than age that explain the
variance in biomarker signatures.
Bioinformatic Analysis of Age-Dependent CSF
Biomarkers
Gene Ontology classification categories derived from this
data set are shown in Table 2. By this preliminary analy-
sis, the most significant ontological relationships among
the age-dependent biomarkers involved inflammation
and response to injury. In addition, significant alterations
in several complement components indicated that com-
plement activation may affect the biomarker profile in
aging CSF. Additional biomarkers are found in gene on-
tology categories related to proteolysis, response to ox-
idative stress, and autophagy.
Discussion
CSF Proteome Detected by SOMAmer Array
This study represents the first broad survey of CSF pro-
teins using an oligonucleotide SOMAmer array. The
menu of SOMAmers used in this study was not initially
intended to be used specifically for studies of the CNS,
nor was the distribution of targets intended to reflect the
relative distribution of classes of proteins in the entire
proteome. Nonetheless, we fortuitously detected 248 pro-
teins in CSF samples of normal, aging adults 21 to 85
years of age and identified significant trends in abun-
dance over this age range for 82 proteins. Although the
age dependencies of some of these CSF biomarkers,
such as Activin A,16 have been reported previously in
Table 2. Continued
Protein 1 2 3 4 5 6
Angiogenin ●
HMW kininogen ● ● ●
TRAILR4
FSH
NovH
Gr. V Phospholipase A2
Cystatin C ●
DRR1
Troponin I
IGF.I ● ●
BMP.14
PTN ●
MIP.3b ● ● ●
*1  GO:0009611 response to wounding; 2  GO:0006954 inflamm
immune response; 5  GO:0006956 complement activation; 6  GO:004
wound healing; 9  GO:0007596 blood coagulation; 10  GO:0008284
12  GO:0030334 regulation of cell migration; 13  GO:0001944 vasc
GO:0006508 proteolysis; 16  GO:0006979 response to oxidative stresssmaller studies, most are novel biomarkers of aging thatare prominently associated with immune system activa-
tion or response to injury.
There are several advantages of this approach over
mass spectrometry and immunoassays. First, all of the anal-
yses performed on these samples required only 64 L of
CSF, whereas mass spectrometric studies achieving simi-
larly detailed characterizations would probably require
greater than 100 times as much sample. Second, no exist-
ing immunoassay platform has been demonstrated to op-
erate at such a high multiplex in CSF as this approach.
However, there are also potential pitfalls inherent in inter-
preting any data derived from an assay based on novel
technology. It is not known, for example, how protein post-
translational modifications (PTMs) will affect aptamer bind-
ing in all cases, and heavily phosphorylated or glycosylated
proteins may not be detected with aptamers used here that
were created to bind to native proteins. Robustness to
PTMs is a problem for any assay based on affinity reagents,
however, and not just for aptamer-based assays. Therefore,
work is ongoing to create PTM-specific SOMAmers, analo-
gous to PTM-specific antibodies, to address more specifi-
cally the question of PTMs in studies such as this.
A total of 248 proteins were quantified at signals at least
two-fold over background out of the 813 proteins targeted
by the array. The remaining proteins were presumably not
present in samples at concentrations greater than the lower
limit of quantification (median limit of 1 pmol/L, ranging from
10fM-1 mol/L for the array; data for all analytes detailed in
Gold et al27). Further optimization of the assay for CSF could
improve sensitivity and quantify more proteins, and this
work is ongoing. The menu of SOMAmers to measure spe-
cific proteins is expanding, and more CNS-specific proteins
have been added to the menu of 1000 targets in the
months since these experiments were performed.
Biology and Pathology of CSF Aging Biomarkers
Before interpreting the biological significance of the re-
sults of the SOMAmer array, preanalytical variables
e ontology classification*
8 9 10 11 12 13 14 15 16 17
● ●
● ● ● ●
●
● ● ●
●
sponse; 3  GO:0006952 defense response; 4  GO:0045087 innate
gulation of cell proliferation; 7  GO:0040007 growth; 8  GO:0042060
e regulation of cell proliferation; 11  GO:0016485 protein processing;
development; 14  GO:0050878 regulation of body fluid levels; 15 
GO:0006914 autophagy.Gen
7
●
●
●
atory re
2127 re
positivshould be examined, to minimize bias. Clinically, the sub-
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examined physically and cognitively, supporting the con-
tention that the data collected here represents “normal
aging” rather than pathological changes. Still, it is possi-
ble that some of the elderly patients in the study could
have had undetected, preclinical neurodegenerative dis-
ease, and it is thus possible (but unlikely) that some of
these age-correlated biomarkers are instead disease-
correlated biomarkers. A second possible source of pre-
analytical variation in any study of CSF is blood contam-
ination caused by bleeding into the thecal space during
the collection procedure. A reasonable check for this
confounder is assessment of CSF apolipoprotein B
(apoB), as it is present in blood but not in normal CSF.19
Although absolute concentration of apoB was not deter-
mined in the samples used in this study, the relative RFU
signals corresponding to apoB concentrations in all sam-
ples were measured (Figure 2). Because the relative
apoB signal in all samples were near the assay’s limit of
detection and did not vary appreciably with age, any
blood contamination in these samples would appear to
be small and uniform on average across ages, and would
thus not confound attempts to identify apparent age-
dependent trends in other biomarkers. It is possible, how-
ever, that an age-invariant rate of blood contamination
could lead to spurious age-related signals if a putative
biomarker varied in concentration in the blood; but the
absolute level of blood contamination in these samples,
as assessed by red blood cell counts, was low enough to
make this possibility unlikely (see Supplemental Figure
S1 at http://ajp.amjpathol.org). In addition, although sev-
eral of the biomarkers reported here to increase with
increasing age in CSF have been reported to behave
similarly in plasma (Activin A,16 von Willebrand factor35),
others displayed changes in CSF opposite from the ex-
pected age-related changes in serum (Troponin I,36 Cys-
tatin C37), indicating that simple contamination with blood
cannot be responsible for all of the CSF results. Finally,
no target analyte concentration was significantly corre-
lated with RBC counts (data not shown), indicating that
contamination with blood was not reliably associated with
increased biomarker signals.
Assuming that preanalytical variation is thus mini-
mal, the data clearly indicate that several CSF proteins
correlate with chronologic age, and could reflect nor-
mal CNS aging. In specific, Gene Ontology analysis
indicated that markers of inflammation and wound re-
pair are highly represented in the age-correlated pro-
teins. Apart from supporting previous work indicating a
role for inflammatory processes in CNS aging and de-
generation,38,39 this finding should support the gener-
ation of many hypotheses about the interplay of tissue
injury, inflammation, and the process of CNS injury, as
well as suggest biomarkers that can be measured to
interrogate the system.
Several of the age-correlated proteins detected here
have been reported in CSF in a variety of clinical con-
texts but not always correlated with age, such as HGF
(aging,17 neoplasia,40 vascular disorders,41 inflamma-
tion42), von Willebrand factor (infarction43), comple-
ment component C3a (aging18), MIP-3b (inflamma-tion44,45), and SLPI (infection46). The increase in FSH
observed in the female subjects is likewise in accord
with well-known pituitary increases in FSH expression
resulting from menopause.
von Willebrand factor demonstrated the largest aver-
age RFU signal increase between young and old sub-
jects, with average RFU signals increasing almost 200%
between 21 and 85 years of age, based on regression
analysis. von Willebrand factor is a very large molecule,
forming multimers with a monomer molecular weight of
260 kDa, so it is very unlikely that it crosses the blood–
brain barrier into the CSF. Instead, it may derive from
platelets or subendothelial connective tissue in response
to tissue injury; the finding of increased fibrinogen in CSF
with increasing age (Table 1) corroborates this interpre-
tation, because fibrinogen plays a role in the coagulation
cascade after tissue injury. These findings alone, how-
ever, do not prove that a chronic pattern of low-grade
tissue or vascular injury accompanies normal aging, so
further targeted experiments will be needed to support
this hypothesis.
It is important to consider that although a number of
biomarkers were significantly correlated with chronologic
age, there was still substantial variation in the data that
was not explained by age alone, as evidenced by the
results of principal component analysis and principal
component regression. This raises the question of
whether a biomarker regression model can predict a
“biological” CNS age, rather than just chronological CNS
age. If the factors responsible for the observed variance
in this model are reproducible and correlated with real
biological effects, then regression-predicted age may, in
fact, indicate whether one’s “biological” and chronologi-
cal CNS ages are discrepant even if the hidden effects
are not yet understood. Such a biomarker profile, if ap-
propriately validated, could thus be useful in studies of
normal and pathological CNS aging.
Several approaches are currently underway to explain
more completely the variance in correlations between
proteins identified here and chronologic age. First, a
number of other pathological processes, such as oxi-
dative stress, could be responsible; thus we are be-
ginning to correlate the findings of this SOMAmer array
with measures of oxidative stress, such as F2-isopros-
tanes. Second, although the subjects included in this
study were judged to be cognitively normal by clinical
testing, it would be useful to understand whether mild
variation in normal performance on cognitive tests is
correlated with discrepancies between a subject’s
chronological age and the “biological” CNS age ex-
trapolated from biomarker data; these studies are cur-
rently underway. Finally, the age-associated proteins
discovered in this approach are being quantified in
subject cohorts who have suspected or confirmed,
early- or late-stage neurodenegerative disorders such
as AD and PD. If these patients demonstrate significant
biological and chronological CNS age discrepancies,
this approach may eventually serve as an adjunct to
studying and diagnosing suspected or overt neurode-
generative disease.
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